Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 20 | 2025 | 346 | 2.980 |
Why?
|
| Hydroxyurea | 2 | 2020 | 87 | 0.710 |
Why?
|
| Recombinases | 3 | 2025 | 26 | 0.630 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2025 | 72 | 0.490 |
Why?
|
| Glioma | 4 | 2007 | 536 | 0.380 |
Why?
|
| Erythrocyte Aging | 1 | 2011 | 8 | 0.350 |
Why?
|
| Hematologic Diseases | 2 | 2025 | 82 | 0.350 |
Why?
|
| Antisickling Agents | 1 | 2011 | 18 | 0.350 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 145 | 0.350 |
Why?
|
| Acetamides | 1 | 2011 | 48 | 0.340 |
Why?
|
| Hemolysis | 1 | 2011 | 114 | 0.340 |
Why?
|
| Cytapheresis | 1 | 2009 | 1 | 0.330 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 208 | 0.300 |
Why?
|
| beta-Globins | 2 | 2025 | 9 | 0.290 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 136 | 0.290 |
Why?
|
| Anemia | 2 | 2022 | 350 | 0.280 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2007 | 7 | 0.280 |
Why?
|
| Capacity Building | 2 | 2025 | 24 | 0.270 |
Why?
|
| Brain Stem Neoplasms | 1 | 2007 | 47 | 0.260 |
Why?
|
| Child | 25 | 2025 | 25875 | 0.260 |
Why?
|
| Cerebral Infarction | 3 | 2014 | 46 | 0.240 |
Why?
|
| Child, Preschool | 17 | 2024 | 14896 | 0.240 |
Why?
|
| Pain | 4 | 2017 | 461 | 0.230 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 20 | 0.230 |
Why?
|
| Alleles | 3 | 2025 | 1694 | 0.230 |
Why?
|
| Neonatal Screening | 2 | 2017 | 193 | 0.220 |
Why?
|
| Blood Transfusion | 3 | 2021 | 296 | 0.210 |
Why?
|
| Magnesium Sulfate | 1 | 2014 | 51 | 0.210 |
Why?
|
| Menorrhagia | 1 | 2024 | 82 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 1252 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 126 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 3869 | 0.200 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 134 | 0.200 |
Why?
|
| Adolescent | 18 | 2024 | 20587 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 32 | 0.190 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1166 | 0.180 |
Why?
|
| Angola | 2 | 2018 | 5 | 0.180 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 187 | 0.180 |
Why?
|
| Pediatrics | 3 | 2025 | 1218 | 0.170 |
Why?
|
| Humans | 36 | 2025 | 133492 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 237 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 235 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 471 | 0.170 |
Why?
|
| Malaria | 1 | 2021 | 102 | 0.170 |
Why?
|
| HIV Infections | 2 | 2022 | 2023 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 175 | 0.160 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 65 | 0.160 |
Why?
|
| Iron | 1 | 2022 | 303 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2010 | 127 | 0.160 |
Why?
|
| Malnutrition | 1 | 2022 | 221 | 0.160 |
Why?
|
| Hematology | 1 | 2018 | 43 | 0.150 |
Why?
|
| Hemoglobins | 2 | 2022 | 322 | 0.140 |
Why?
|
| Paper | 1 | 2017 | 7 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2014 | 1381 | 0.130 |
Why?
|
| Brain Diseases | 1 | 2010 | 310 | 0.130 |
Why?
|
| Female | 19 | 2024 | 71527 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1730 | 0.130 |
Why?
|
| Male | 18 | 2024 | 65634 | 0.130 |
Why?
|
| Platelet Count | 2 | 2022 | 141 | 0.130 |
Why?
|
| Quality Improvement | 3 | 2024 | 701 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2853 | 0.120 |
Why?
|
| Infant | 9 | 2024 | 13254 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 32 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 294 | 0.120 |
Why?
|
| Patient Care | 2 | 2018 | 101 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 336 | 0.120 |
Why?
|
| Magnesium | 1 | 2015 | 122 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 1078 | 0.110 |
Why?
|
| Prognosis | 4 | 2024 | 5052 | 0.110 |
Why?
|
| Length of Stay | 3 | 2015 | 1392 | 0.110 |
Why?
|
| Quality of Life | 3 | 2017 | 2160 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 17562 | 0.100 |
Why?
|
| Body Height | 1 | 2014 | 228 | 0.100 |
Why?
|
| Lamivudine | 2 | 2022 | 25 | 0.100 |
Why?
|
| Neoplasms | 2 | 2014 | 2987 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 3097 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8633 | 0.090 |
Why?
|
| Global Health | 1 | 2017 | 616 | 0.090 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 118 | 0.090 |
Why?
|
| Young Adult | 6 | 2023 | 9968 | 0.090 |
Why?
|
| beta-Thalassemia | 1 | 2011 | 30 | 0.090 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 14 | 0.090 |
Why?
|
| Risk Factors | 6 | 2024 | 10967 | 0.090 |
Why?
|
| Acute Chest Syndrome | 1 | 2011 | 10 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2015 | 1654 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 614 | 0.090 |
Why?
|
| Hematocrit | 1 | 2011 | 114 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1344 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 791 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 5451 | 0.080 |
Why?
|
| Body Weight | 1 | 2014 | 1035 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 750 | 0.080 |
Why?
|
| Chest Pain | 1 | 2009 | 133 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 313 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 569 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 818 | 0.070 |
Why?
|
| Brain | 1 | 2010 | 3220 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2014 | 552 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 240 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2023 | 1097 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 203 | 0.060 |
Why?
|
| Syndrome | 1 | 2009 | 1173 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2017 | 1250 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 503 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 1408 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3448 | 0.060 |
Why?
|
| Adult | 6 | 2024 | 31765 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 571 | 0.050 |
Why?
|
| Hospitals, Special | 1 | 2014 | 12 | 0.050 |
Why?
|
| Narcotics | 1 | 2014 | 64 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 153 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 228 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 84 | 0.050 |
Why?
|
| Point Mutation | 1 | 2024 | 357 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2023 | 88 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 233 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 158 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 234 | 0.050 |
Why?
|
| Hypotension | 1 | 2014 | 186 | 0.050 |
Why?
|
| Middle Aged | 5 | 2015 | 29063 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 316 | 0.040 |
Why?
|
| Informed Consent | 1 | 2014 | 344 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 348 | 0.040 |
Why?
|
| Optic Nerve Glioma | 1 | 2001 | 22 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 812 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 568 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2010 | 280 | 0.040 |
Why?
|
| United States | 3 | 2023 | 11758 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 423 | 0.040 |
Why?
|
| Probability | 1 | 2010 | 328 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 725 | 0.040 |
Why?
|
| Aged | 3 | 2011 | 21568 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 486 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 1463 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 794 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 194 | 0.040 |
Why?
|
| Death Certificates | 1 | 1998 | 10 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 1381 | 0.030 |
Why?
|
| Isoelectric Focusing | 1 | 2017 | 24 | 0.030 |
Why?
|
| Saponins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Sulfites | 1 | 2017 | 31 | 0.030 |
Why?
|
| Canada | 1 | 1998 | 342 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2017 | 77 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 139 | 0.030 |
Why?
|
| Texas | 2 | 2007 | 3668 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2011 | 13088 | 0.030 |
Why?
|
| Sex Factors | 1 | 2001 | 1354 | 0.030 |
Why?
|
| Patient Selection | 1 | 2010 | 732 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2153 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1909 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 323 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 320 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 414 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 256 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2014 | 39 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 66 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2015 | 180 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 833 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 3417 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 109 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 205 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 250 | 0.030 |
Why?
|
| Intelligence | 1 | 2014 | 107 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 776 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 567 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 2678 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 540 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 199 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 223 | 0.020 |
Why?
|
| Incidence | 1 | 2001 | 3393 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 561 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1068 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 87 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 3042 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 327 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 3724 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 27 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 46 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 81 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 102 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 120 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 134 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 309 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1468 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 965 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 814 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 257 | 0.020 |
Why?
|
| SEER Program | 1 | 2007 | 222 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 437 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6584 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 556 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 2203 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2004 | 24 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2004 | 25 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 141 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1053 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2004 | 111 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3758 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1351 | 0.010 |
Why?
|
| Ependymoma | 1 | 2004 | 176 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 6336 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 740 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1586 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 1466 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1870 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 2715 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 3361 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6545 | 0.010 |
Why?
|